Annotation follows sequencing. Annotation is the first step towards integrating comprehensive molecular information into patient care. Annotation is the process of marking the genes and other biological features in a DNA sequence. The information produced by the annotation enables us to know more about the complexity of cancer than ever before. In the past, there were only a handful of “biomarkers” to guide therapy in a few cancer types. Great strides have been made in annotation technology and there is a growing number of molecular targets, and therapies against those targets, across all cancer types.
In cancer, the genomes of affected cells are rearranged in complex and unpredictable ways. NGS is a revolutionary new tool that can identify previously unknown point mutations in a variety of genes in cancer. Annotation compares the sequencing results to the growing collection of human genome sequences in multiple databases by utilizing detection methods that simultaneously measure several hundred thousand sites throughout the genome.
DNA SEQ has an expanded version of the annotation process. We seek to enhance the precision of analysis by focusing on signaling network of cancer cell. In this process we apply the vast amount of crystallographic data which allows us to view genomic mutation of cancer patient not in the context of linear sequence but in the context of the three dimensional structure that is in the context of real living cell. We focus on “signaling switches”-kinases and how they if mutated miscommunicate with the vast network of the cancer cell. Our “three dimensional lenses”, allows us to asses the precise functionality of mutant leading to aberrant signaling switch and how this results in miscommunication along the vast signaling network. Following that we arrive to precise “genetic signature of patient responder” to a particular kinase inhibitor.